published 30-day FRN

8307

Federal Register / Vol. 85, No. 30 / Thursday, February 13, 2020 / Notices
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Office of Research
Infrastructure Programs Special Emphasis
Panel; Office of Research Infrastructure
Programs (ORIP) Special Emphasis Panel:
Applications for Scientific Conferences.
Date: March 20, 2020.
Time: 11:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Dr., Bethesda,
MD 20892 (Telephone Conference Call).
Contact Person: Kenneth Ryan, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3218,
MSC 7717, Bethesda, MD 20892, (301) 435–
0229, [email protected].
(Catalogue of Federal Domestic Assistance
Program Nos. 93.14, Intramural Research
Training Award; 93.22, Clinical Research
Loan Repayment Program for Individuals
from Disadvantaged Backgrounds; 93.232,
Loan Repayment Program for Research
Generally; 93.39, Academic Research
Enhancement Award; 93.936, NIH Acquired
Immunodeficiency Syndrome Research Loan
Repayment Program; 93.187, Undergraduate
Scholarship Program for Individuals from
Disadvantaged Backgrounds, National
Institutes of Health, HHS)
Dated: February 7, 2020.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2020–02860 Filed 2–12–20; 8:45 am]
BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Submission for OMB Review; 30-Day
Comment Request; NCI Genomic Data
Commons (GDC) Data Submission
Request Form (National Cancer
Institute)
AGENCY:

National Institutes of Health,

HHS.
ACTION:

Notice.

In compliance with the
Paperwork Reduction Act of 1995, the
National Institutes of Health (NIH) has
submitted to the Office of Management
and Budget (OMB) a request for review
and approval of the information
collection listed below.
DATES: Comments regarding this
information collection are best assured
of having their full effect if received
within 30-days of the date of this
publication.
SUMMARY:

Written comments and/or
suggestions regarding the item(s)
contained in this notice, especially
regarding the estimated public burden
and associated response time, should be
directed to the: Office of Management
and Budget, Office of Regulatory Affairs,
[email protected] or by
fax to 202–395–6974, Attention: Desk
Officer for NIH.
FOR FURTHER INFORMATION CONTACT: To
request more information on the
proposed project or to obtain a copy of
the data collection plans and
instruments, contact: Zhining Wang,
Ph.D., Project Officer, Center for Cancer
Genomics (CCG), National Cancer
Institute, Building 31 Room 3A20, 31
Center Drive, Bethesda, MD 20814 or
call non-toll-free number 301–402–1892
or email your request, including your
address to: [email protected].
SUPPLEMENTARY INFORMATION: This
proposed information collection was
previously published in the Federal
Register on December 2, 2019 page
65990 (Vol. 84 No. 231 FR 65990 and
allowed 60 days for public comment. No
ADDRESSES:

public comments were received. The
purpose of this notice is to allow an
additional 30 days for public comment.
The National Cancer Institute (NCI),
National Institutes of Health, may not
conduct or sponsor, and the respondent
is not required to respond to, an
information collection that has been
extended, revised, or implemented on or
after October 1, 1995, unless it displays
a currently valid OMB control number.
In compliance with Section
3507(a)(1)(D) of the Paperwork
Reduction Act of 1995, the National
Institutes of Health (NIH) has submitted
to the Office of Management and Budget
(OMB) a request for review and
approval of the information collection
listed below.
Proposed Collection: NCI Genomic
Data Commons (GDC) Data Submission
Request Form, 0925–0752, Expiration
Date 5/31/2020, EXTENSION, National
Cancer Institute (NCI), National
Institutes of Health (NIH).
Need and Use of Information
Collection: The purpose of the NCI
Genomic Data Commons (GDC) Data
Submission Request Form is to provide
a vehicle for investigators to request
submission of their cancer genomic data
into the GDC in support of data sharing.
The purpose is to also provide a
mechanism for the GDC Data
Submission Review Committee to
review and assess the data submission
request for applicability to the GDC
mission. The scope of the form involves
obtaining information from investigators
that: (1) Would like to submit data about
their study into the GDC, (2) are
affiliated with studies that adhere to
GDC data submission conditions. The
benefits of the collection are that it
provides the needed information for
investigators to understand the types of
studies and data that the GDC supports,
and that it provides a standard
mechanism for the GDC to assess
incoming data submission requests.
OMB approval is requested for 3
years. There are no costs to respondents
other than their time. The total
estimated annualized burden hours are
50 hours.

ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents

jbell on DSKJLSW7X2PROD with NOTICES

Type ofrespondent

Number of
responses
per
respondent

Average time
per response
(in hours)

Total annual
burden hour

Investigator ......................................................................................................

200

1

15/60

50

Total ..........................................................................................................

........................

200

........................

50

VerDate Sep<11>2014

18:34 Feb 12, 2020

Jkt 250001

PO 00000

Frm 00063

Fmt 4703

Sfmt 4703

E:\FR\FM\13FEN1.SGM

13FEN1

8308

Federal Register / Vol. 85, No. 30 / Thursday, February 13, 2020 / Notices

Dated: February 6, 2020.
Diane Kreinbrink,
Project Clearance Liaison, National Cancer
Institute, National Institutes of Health.
[FR Doc. 2020–02911 Filed 2–12–20; 8:45 am]
BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Request for Information: Stakeholder
Input on Opportunities for Increased
Collaboration to Advance Prevention
Research
AGENCY:

National Institutes of Health,

HHS.
ACTION:

Notice.

The National Institutes of
Health (NIH), Office of the Director,
Office of Disease Prevention (ODP)
issues this Request for Information (RFI)
to identify opportunities to foster and
engage in partnerships and dialogue
with stakeholders to advance prevention
research. The ODP hopes this will help
us determine areas where we can
collaboratively advance prevention
research priorities, training
opportunities, and better meet the needs
of our stakeholders. The ODP invites
input from researchers in academia and
industry, health care professionals,
patient advocates and advocacy
organizations, scientific or professional
organizations, federal agencies, and
other interested members of the public.
Organizations are strongly encouraged
to submit a single response that reflects
the views of the organization and
membership as a whole.
DATES: The ODP’s RFI is open for public
comment for a period of 45 days.
Responses must be received by 5:00
p.m. ET on March 29, 2020 to ensure
consideration.
SUMMARY:

Comments must be
submitted electronically at https://
prevention.nih.gov/StakeholderRFI.
FOR FURTHER INFORMATION CONTACT:
Please direct all inquiries to Marie
Rienzo, M.A.; ODP, NIH; Phone: 301–
827–5561; email: [email protected].
SUPPLEMENTARY INFORMATION: To ensure
consideration, responses must be
submitted electronically at https://
prevention.nih.gov/StakeholderRFI.
Respondents will receive a confirmation
of their submission but will not get
individualized feedback. All
respondents are encouraged to sign up
for the ODP listserv to receive
information about the ODP’s latest
activities.

jbell on DSKJLSW7X2PROD with NOTICES

ADDRESSES:

VerDate Sep<11>2014

18:34 Feb 12, 2020

Jkt 250001

In accordance with 42 U.S.C. 282(f) of
the Public Health Service Act, as
amended, the mission of the ODP is to
improve public health by increasing the
scope, quality, dissemination, and
impact of prevention research supported
by the NIH. The ODP’s Strategic Plan FY
2019–2023 includes six strategic
priorities and three cross-cutting themes
that guide the activities of the Office.
The cross-cutting themes represent
areas of opportunity for the ODP to
serve as a catalyst for developing,
coordinating, and implementing new
activities and to better integrate disease
prevention into trans-NIH initiatives.
• Stimulate research to address the
leading causes and risk factors for
premature mortality and morbidity.
• Support activities that strengthen
research to address health disparities.
• Promote prevention-related
dissemination and implementation
research.
The ODP’s six priorities represent the
breadth of our activities and allow for
emerging areas of opportunity to be
incorporated into Office activities.
• Systematically monitor NIH
investments in prevention research and
the progress and results of that research.
• Identify prevention research areas
for investment or expanded effort by the
NIH.
• Promote the use of the best
available methods in prevention
research and support the development
of better methods.
• Promote collaborative prevention
research projects and facilitate
coordination of such projects across the
NIH and with other public and private
entities.
• Promote and facilitate tobacco
regulatory science and tobacco
prevention research.
• Communicate the importance and
value of prevention research,
disseminate prevention research
resources and programs, and build and
enhance relationships with key
stakeholders.
The definition of prevention research
used by the ODP encompasses both
primary and secondary prevention.
Primary prevention includes research
designed to promote health; identify
risk factors for developing a new health
condition (e.g., disease, disorder,
injury); and prevent the onset of a new
health condition. Secondary prevention
includes research designed to identify
risk factors for the progression or
recurrence of a health condition and
detecting and preventing progression of
an asymptomatic or early-stage
condition.
The ODP helps develop and
coordinate prevention research

PO 00000

Frm 00064

Fmt 4703

Sfmt 4703

activities including, but not limited to,
funding opportunities, workshops, and
conferences across the NIH and with
other public and private organizations.
The Office is looking to build and
leverage its resources and partnerships
to further support prevention research.
Input received from this RFI will help
the ODP identify opportunities for
increased dialogue, partnerships,
collaboration, and engagement with
stakeholders. The ODP hopes this will
help us pinpoint areas where
collaborative efforts can help advance
prevention research.
Information Requested
The ODP is seeking input on the
following topics/areas:
1. Please comment on the top 2–3
strategies for increasing collaboration
and engagement between the ODP and
your organization. The ODP is
particularly interested in opportunities
to advance areas that address the top
disease risk factors in the United States,
as well as efforts to reduce health
disparities, improve quality and access
to care for major contributors to
morbidity and mortality, and help
address social determinants of health.
2. Please provide suggestions for how
the ODP can foster high-quality
collaborative prevention research and in
what areas (e.g., screening for disease or
risk factors, economics of prevention,
prevention methods and measurement
research, training efforts).
3. The ODP has developed resources
to educate researchers and promote
prevention research. The Office is
looking for opportunities to collaborate
with organizations to create new
materials to achieve these goals. Please
identify the 2–3 resources (e.g., training
courses, fact sheets, infographics,
videos) that would be most useful for
your organization.
4. The ODP often presents and
exhibits at various scientific meetings.
Please identify scientific meetings that
might benefit from ODP participation.
5. Optional: Please indicate if you are a:
• Researcher in academia
• Researcher in industry
• Health care professional
• Patient advocate
• Staff member at a scientific or
professional organization
• Federal government employee
Responses to this RFI are voluntary
and may be submitted anonymously.
Proprietary, classified, confidential, or
sensitive information should not be
included in responses. We will post a
summary report of the comments on the
ODP website. Any personal identifiers
(personal names, email addresses, etc.)

E:\FR\FM\13FEN1.SGM

13FEN1